Form 4: Sutro Biopharma CEO Plans RSU Exercise Under 10b5-1

Sutro Biopharma's CEO, Jane Chung, filed a Form 4 detailing a future, pre-scheduled exercise of restricted stock units and net acquisition of common stock.

Summary

• Jane Chung, CEO and Director of Sutro Biopharma, Inc. (STRO), is scheduled to exercise 18,750 Restricted Stock Units (RSUs) on August 9, 2025, as part of a pre-arranged Rule 10b5-1 trading plan.
• Each RSU represents a contingent right to receive one share of the issuer's common stock upon settlement.
• Concurrently, 6,708 shares of common stock are scheduled to be withheld by the issuer to satisfy income tax withholding and remittance obligations related to the RSU settlement.
• This will result in a net acquisition of 12,042 shares (18,750 acquired minus 6,708 withheld for taxes) of common stock for Jane Chung.
• Following these transactions, Jane Chung will directly beneficially own 110,350 shares of Sutro Biopharma common stock.
• The RSUs vested or vest as to 1/4th of the total award annually beginning on August 9, 2022, subject to the reporting person's provision of service to the issuer on each vesting date.

Sentiment

Score: 6

Explanation: The filing reports a pre-scheduled, routine RSU exercise and net acquisition of shares by the CEO under a Rule 10b5-1 plan. While it increases insider ownership, its pre-planned nature makes it a neutral, expected event rather than a strong signal of new confidence.

Positives

• CEO Jane Chung is scheduled to exercise Restricted Stock Units under a Rule 10b5-1 plan, indicating a pre-planned vesting event and conversion of equity incentives into common stock.
• The transaction will result in a net acquisition of 12,042 shares of common stock by the CEO, increasing her direct beneficial ownership and aligning her interests with shareholders.

Negatives

• 6,708 shares are scheduled to be disposed of to cover tax liabilities, which is a common and expected practice for RSU settlements and not a discretionary sale by the insider.

Future Outlook

NA

Industry Context

NA

Stakeholder Impact

• Shareholders: Increased direct ownership by the CEO may be viewed positively as it aligns management's interests with shareholders.
• Employees: The RSU vesting and exercise demonstrate the company's equity compensation program in action.

Key Dates

Recommendation

This Form 4 filing details a pre-scheduled, routine insider transaction under a Rule 10b5-1 plan, where the CEO will exercise vested Restricted Stock Units and cover tax obligations. While it results in a net increase in the CEO's direct ownership, its pre-planned and routine nature means it does not provide new fundamental information to warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate as it does not present a strong buy or sell signal.

Keywords

Sutro Biopharma, STRO, Jane Chung, Form 4, Insider Transaction, Restricted Stock Units, RSU, Equity Compensation, CEO, Director, Stock Ownership, 10b5-1 plan